Stifel Starts Lexeo Therapeutics (LXEO) at Buy, 'Catalyst-Rich 2024'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
Go back to Stifel Starts Lexeo Therapeutics (LXEO) at Buy, 'Catalyst-Rich 2024'
November 28, 2023 6:42 AM EST
Chardan Capital Markets analyst Geulah Livshits initiates coverage on Lexeo Therapeutics (NASDAQ: LXEO) with a Buy rating and a price target of $23.00.
The analyst comments "
We initiate coverage of Lexeo Therapeutics with a Buy rating and a $23 PT on the potential of its AAV gene therapy (GT) pipeline to durably treat the underlying cause of disease in genetically defined forms of cardiomyopathy (CM) and Alzheimers disease (AD) representing sizable patient populations with high... More
November 28, 2023 12:59 AM EST
(Updated - November 28, 2023 6:54 AM EST)
RBC Capital analyst Luca Issi initiates coverage on Lexeo Therapeutics (NASDAQ: LXEO) with a Outperform rating and a price target of $22.00.
The analyst commented, "We are initiating at Outperform, Speculative Risk with a $22 PT given:... More
November 28, 2023 12:58 AM EST
JPMorgan analyst Tessa Romero initiates coverage on Lexeo Therapeutics (NASDAQ: LXEO) with a Overweight rating and a price target of $20.00.
For an analyst ratings summary and ratings history on Lexeo Therapeutics click here. For more ratings news on Lexeo Therapeutics click here.
Shares of Lexeo Therapeutics closed at $11.00 yesterday.
...
More
